IJTLD OPEN最新文献_第3页

TB among refugees from Ukraine in European countries 欧洲国家乌克兰难民中的结核病

IJTLD OPEN Pub Date : 2024-04-01 DOI: 10.5588/ijtldopen.24.0062

G. D. Vries, J.-P. Guthmann, B. Häcker, B. Hauer, K. Nordstrand, A. Nowiński, H. Soini

{"title":"TB among refugees from Ukraine in European countries","authors":"G. D. Vries, J.-P. Guthmann, B. Häcker, B. Hauer, K. Nordstrand, A. Nowiński, H. Soini","doi":"10.5588/ijtldopen.24.0062","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0062","url":null,"abstract":"BACKGROUNDSince the Russian Federation’s invasion of Ukraine, millions of refugees have moved to neighbouring European countries. We assessed the burden of TB in these refugees and surveyed screening approaches.METHODSWe conducted a survey among 30 European Union/European Economic Area and 13 other European countries, requesting population data on migrant residents and refugees with country of birth (COB) Ukraine, the number of TB notifications among people\u0000 with COB Ukraine and countries’ screening policies for refugees from Ukraine.RESULTSIn 2021, the number of migrants born in Ukraine was 1.7 million in the 34 responding countries, and increased with 5.2 million refugees from\u0000 Ukraine to 6.9 million in 2022. These countries notified 207 TB cases in people with COB Ukraine in 2021 (TB notification rate 12.0/100,000) and 887 in 2022 (TB notification rate 12.8/100,000), of which 228 (26%) had multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB). TB notification\u0000 rates were higher in countries advising screening for all (16.9/100,000) or specific groups of refugees from Ukraine (14.7/100,000) compared to those without screening (7.2/100,000).CONCLUSIONTB rates found in people from Ukraine\u0000 were lower than the expected rate of 44 per 100,000, but higher in host countries recommending screening. Our study underscores the need for adequate TB health services for refugees from Ukraine to ensure tailored diagnosis and treatment, especially for MDR/RR-TB.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140769446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2022 TB programme review in Pakistan: strengthening governance, with better patient diagnosis and treatment 2022 年巴基斯坦结核病计划审查：加强治理，改善患者诊断和治疗

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.23.0587

M. van den Boom, K. Bennani, C. Sismanidis, C. Gunneberg, L. Khawaja, M.A. Safdar, C. Muhwa, E. Heldal, D.M. Cirillo, A.W. Khan, R. Fatima, B.J. Khan, S. Tahseen, M.G. ElMedrek, Y. Hutin

{"title":"2022 TB programme review in Pakistan: strengthening governance, with better patient diagnosis and treatment","authors":"M. van den Boom, K. Bennani, C. Sismanidis, C. Gunneberg, L. Khawaja, M.A. Safdar, C. Muhwa, E. Heldal, D.M. Cirillo, A.W. Khan, R. Fatima, B.J. Khan, S. Tahseen, M.G. ElMedrek, Y. Hutin","doi":"10.5588/ijtldopen.23.0587","DOIUrl":"https://doi.org/10.5588/ijtldopen.23.0587","url":null,"abstract":"BACKGROUNDIn Pakistan, 84% of healthcare is provided by the private sector. We conducted an epidemiological and programme review for TB to document progress and guide further efforts.METHODSSurveillance\u0000 and data systems were assessed before analysing epidemiological data. We reviewed the programme at federal, provincial and peripheral levels and compiled national data along with WHO estimates to describe the evolution of epidemiological and programme indicators.RESULTSIn\u0000 2021, of the estimated number of TB cases, 55% of overall cases and 18% of drug-resistant cases were diagnosed and treated respectively. The contribution of the private sector in case detection increased from 30% in 2017 to 40% by 2021. For newly diagnosed pulmonary TB cases, the overall proportion\u0000 of confirmed cases was 52%. In 2021, testing for rifampicin resistance among confirmed cases was 66% for new and 84% for previously treated patients. The treatment success rate exceeded 90% for drug susceptible TB. The main challenges identified were a funding gap (60% in 2021–2023),\u0000 fragmented electronic systems for data collection and suboptimal coordination among provinces.CONCLUSIONSThe main challenges prevent further progress in controlling TB. By addressing these, Pakistan could improve coverage of interventions,\u0000 including diagnosis and treatment. Bacteriological confirmation using recommended diagnostics also requires further optimisation.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140270677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspectives from the 2nd International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes 第二届国际结核病后专题讨论会的观点：动员宣传和研究以改善成果

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.23.0619

B.W. Allwood, R. Nightingale, G. Agbota, S. Auld, G.P. Bisson, A. Byrne, R. Dunn, D. Evans, G. Hoddinott, G. Günther, Z. Islam, J.C. Johnston, G. Kalyatanda, C. Khosa, S. Marais, G. Makanda, O. M. Mashedi, J. Meghji, C. Mitnick, C. Mulder, E. Nkereuwem, O. Nkereuwem, O. B. Ozoh, A. Rachow, K. Romanowski, J. Seddon, I. Schoeman, F. Thienemann, N. F. Walker, D. Wademan, R. Wallis, M. M. van der Zalm

{"title":"Perspectives from the 2nd International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes","authors":"B.W. Allwood, R. Nightingale, G. Agbota, S. Auld, G.P. Bisson, A. Byrne, R. Dunn, D. Evans, G. Hoddinott, G. Günther, Z. Islam, J.C. Johnston, G. Kalyatanda, C. Khosa, S. Marais, G. Makanda, O. M. Mashedi, J. Meghji, C. Mitnick, C. Mulder, E. Nkereuwem, O. Nkereuwem, O. B. Ozoh, A. Rachow, K. Romanowski, J. Seddon, I. Schoeman, F. Thienemann, N. F. Walker, D. Wademan, R. Wallis, M. M. van der Zalm","doi":"10.5588/ijtldopen.23.0619","DOIUrl":"https://doi.org/10.5588/ijtldopen.23.0619","url":null,"abstract":"In 2020, it was estimated that there were 155 million survivors of TB alive, all at risk of possible post TB disability. The 2nd International Post-Tuberculosis Symposium (Stellenbosch, South Africa) was held to increase global awareness and empower TB-affected communities\u0000 to play an active role in driving the agenda. We aimed to update knowledge on post-TB life and illness, identify research priorities, build research collaborations and highlight the need to embed lung health outcomes in clinical TB trials and programmatic TB care services. The symposium was\u0000 a multidisciplinary meeting that included clinicians, researchers, TB survivors, funders and policy makers. Ten academic working groups set their own goals and covered the following thematic areas: 1) patient engagement and perspectives; 2) epidemiology and modelling; 3) pathogenesis of post-TB\u0000 sequelae; 4) post-TB lung disease; 5) cardiovascular and pulmonary vascular complications; 6) neuromuscular & skeletal complications; 7) paediatric complications; 8) economic-social and psychological (ESP) consequences; 9) prevention, treatment and management; 10) advocacy, policy and\u0000 stakeholder engagement. The working groups provided important updates for their respective fields, highlighted research priorities, and made progress towards the standardisation and alignment of post-TB outcomes and definitions.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140272434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Psychosocial needs of adolescents living with TB in Peru and South Africa 秘鲁和南非肺结核青少年的社会心理需求

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.23.0443

C. Cintron, G. Hoddinott, B.R. Sinche, R.A. Brown, D. Wademan, J. Seddon, S.S. Chiang

引用次数: 0

Health system costs of providing outpatient care for diabetes in people with TB in the Philippines 菲律宾结核病患者糖尿病门诊治疗的卫生系统成本

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.23.0554

T. Yamanaka, M. C. Castro, J.P. Ferrer, J. A. Solon, S. E. Cox, Y. V. Laurence, A. Vassall

{"title":"Health system costs of providing outpatient care for diabetes in people with TB in the Philippines","authors":"T. Yamanaka, M. C. Castro, J.P. Ferrer, J. A. Solon, S. E. Cox, Y. V. Laurence, A. Vassall","doi":"10.5588/ijtldopen.23.0554","DOIUrl":"https://doi.org/10.5588/ijtldopen.23.0554","url":null,"abstract":"BACKGROUNDDiabetes mellitus (DM) is a known risk factor for active TB. A key activity in the Philippines is to integrate TB services with other disease programmes, with a target of DM screening in 90% of TB cases. However, costs of providing\u0000 DM outpatient services for TB patients are not well known.METHODSWe estimated the costs of providing integrated DM outpatient services within TB services from the health system perspective. Resources for outpatient DM services were valued\u0000 using the bottom-up approach for capital goods, staff time and consumables. Resource quantities were obtained by interviewing 60 healthcare professionals in 11 health facilities in the Philippines.RESULTSThe mean cost per service ranged\u0000 from USD0.53 for DM risk assessment to USD23.72 for oral glucose tolerance test. The cost per case detected for different algorithms varied from USD17.43 to USD80.81. The monthly cost per patient was estimated at USD8.95 to USD12.36.CONCLUSIONOur\u0000 study provides the first estimates of costs for providing integrated DM outpatient services and TB care in a low- and middle-income country. The costs of DM detection in TB patients suggests that it may be useful to further investigate the cost-effectiveness and affordability of service delivery.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140279191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of the private sector on spatial accessibility to chest radiography services in Lima, Peru 私营部门对秘鲁利马胸部放射摄影服务空间可及性的影响

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.23.0460

Y. Xiong, A. Millones, S. Farroñay, I. Torres, D. Acosta, D.R. Jordan, J. Jimenez, C. Wippel, H. E. Jenkins, L. Lecca, C. Yuen

引用次数: 0

Guidelines for the diagnosis and management of post-TB lung disease: a call to action 结核病后肺部疾病诊断和管理指南：行动呼吁

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.24.0093

D.R. Silva, S. Inwentarz

引用次数: 0

Chronic obstructive pulmonary disease related to wood smoke and impact of the combined exposure to tobacco 与木烟有关的慢性阻塞性肺病以及与烟草的综合接触的影响

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.24.0004

C. A. Torres-Duque, C. Jaramillo, A. Caballero, N.J. Proaños-Jurado, M. J. Pareja-Zabala, J.B. Soriano, M. González-García

{"title":"Chronic obstructive pulmonary disease related to wood smoke and impact of the combined exposure to tobacco","authors":"C. A. Torres-Duque, C. Jaramillo, A. Caballero, N.J. Proaños-Jurado, M. J. Pareja-Zabala, J.B. Soriano, M. González-García","doi":"10.5588/ijtldopen.24.0004","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0004","url":null,"abstract":"BACKGROUNDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 highlights the need to explore aetiotypes of chronic obstructive pulmonary disease (COPD) beyond the tobacco-smoking COPD. Exposure to wood smoke (WS) is a risk factor\u0000 for COPD in women, but the effect of the combined exposure to tobacco smoke (TS) in the general population and among COPD patients, and the characteristics of WS-COPD are unclear.METHODThis was an analysis of data from PREPOCOL (Prevalence\u0000 of COPD in Five Colombian Cities Situated at Low, Medium, and High Altitude), a random cross-sectional population-based study (n = 5,539) focusing on the effect of combined WS and TS exposure and WS-COPD characterisation.RESULTSPrevalence\u0000 of COPD was significantly higher in those exposed to both WS and TS (16.0%) than in those exposed to WS (6.7%) or TS (7.8%) only (P < 0.001). Exposure to WS was associated with COPD in men (OR 1.53, P = 0.017). WS-COPD individuals were more frequently female, older, shorter\u0000 and had higher forced expiratory volume in 1 sec (FEV1) (all P < 0.05). Those exposed to both WS and TS had more symptoms and worse airflow limitation (P < 0.001).CONCLUSIONSThis was the first random population-based\u0000 study showing that WS is an associated risk factor for COPD also in men, and that people exposed to both WS and TS have a significantly higher prevalence of COPD. Similarly, COPD subjects exposed to both types of smoke have more symptoms and greater airflow obstruction. This suggests an additive\u0000 effect of WS and TS.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140283228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region 将业务研究作为改善世卫组织欧洲地区耐药结核病治疗成果的机制

IJTLD OPEN Pub Date : 2024-03-01 DOI: 10.5588/ijtldopen.24.0035

G. B. Migliori, O. Korotych, J. Achar, A. Ciobanu, G. Dravniece, M. Germanovych, E. Gurbanova, A. Hovhannesyan, N. Khachatryan, L. Kukša, N. Lomtadze, M.L. Rich, A. Skrahina, A. Yedilbayev

{"title":"Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region","authors":"G. B. Migliori, O. Korotych, J. Achar, A. Ciobanu, G. Dravniece, M. Germanovych, E. Gurbanova, A. Hovhannesyan, N. Khachatryan, L. Kukša, N. Lomtadze, M.L. Rich, A. Skrahina, A. Yedilbayev","doi":"10.5588/ijtldopen.24.0035","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0035","url":null,"abstract":"In 2022, the WHO European Region accounted for 15.1% of all incident rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB) cases. Most occurred in 18 high-priority countries of eastern Europe and central Asia, many of which joined an initiative led by the WHO Regional Office for Europe.\u0000 The aim was to introduce three, fully oral, 9-month modified shorter treatment regimens (mSTR) to treat RR/MDR-TB under operational research conditions. The three regimens were: 1) bedaquiline + linezolid + levofloxacin + clofazimine + cycloserine (BdqLzdLfxCfzCs); 2) BdqLzdLfxCfz + delamanid\u0000 (Dlm) for children over 6 years of age and adults; and 3) DlmLzdLfxCfz for children under 6 years of age. The project aimed to enhance treatment success, facilitate mSTR implementation, promote quality of care and build research capacity, while also contributing to global knowledge on all-oral\u0000 mSTR use. Between April 2020 and June 2022, >2,800 patients underwent mSTR treatment in the WHO European Region. This unique experience promoted further collaboration with national tuberculosis programmes, health authorities, experts and donors within and outside Europe, with a focus on\u0000 implementing operational research and improving the quality of care in high TB burden countries of the region. In the hope of encouraging others to adopt this model, we have described the principles of the initiative, its strengths and weaknesses and next steps.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140267981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB 用异烟肼尿液分光光度法预测成人肺结核患者的血清药代动力学

IJTLD OPEN Pub Date : 2024-02-01 DOI: 10.5588/ijtldopen.23.0361

P. Rao, K. Reed, N. Modi, D. Handler, K. Petros de Guex, S. Yu, L. Kagan, R. Reiss, N. Narayanan, C. A. Peloquin, A. Lardizabal, C. Vinnard, T. A. Thomas, Y. L. Xie, S. Heysell

{"title":"Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB","authors":"P. Rao, K. Reed, N. Modi, D. Handler, K. Petros de Guex, S. Yu, L. Kagan, R. Reiss, N. Narayanan, C. A. Peloquin, A. Lardizabal, C. Vinnard, T. A. Thomas, Y. L. Xie, S. Heysell","doi":"10.5588/ijtldopen.23.0361","DOIUrl":"https://doi.org/10.5588/ijtldopen.23.0361","url":null,"abstract":"BACKGROUNDIsoniazid (INH) is an important drug in many TB regimens, and unfavorable treatment outcomes can be caused by suboptimal pharmacokinetics. Dose adjustment can be personalized by measuring peak serum concentrations; however, the process\u0000 involves cold-chain preservation and laboratory techniques such as liquid chromatography (LC)/mass spectrometry (MS), which are unavailable in many high-burden settings. Urine spectrophotometry could provide a low-cost alternative with simple sampling and quantification methods.METHODSWe\u0000 enrolled 56 adult patients on treatment for active TB. Serum was collected at 0, 1, 2, 4, 6, and 8 h for measurement of INH concentrations using validated LC-MS/MS methods. Urine was collected at 0–4, 4–8, and 8–24 h intervals, with INH concentrations measured using colorimetric\u0000 methods.RESULTSThe median peak serum concentration and total serum exposure over 24 h were 4.8 mg/L and 16.4 mg*hour/L, respectively. Area under the receiver operator characteristic curves for urine values predicting a subtherapeutic serum\u0000 concentration (peak <3.0 mg/L) were as follows: 0–4 h interval (AUC 0.85, 95% CI 0.7–0.96), 0–8 h interval (AUC 0.85, 95% CI 0.71–0.96), and 0–24 h urine collection interval (AUC 0.84, 95% CI 0.68–0.96).CONCLUSIONUrine\u0000 spectrophotometry may improve feasibility of personalized dosing in high TB burden regions but requires further study of target attainment following dose adjustment based on a urine threshold.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140467422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0